Karen Tsai

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised Egnyte, a provider of secure content collaboration and governance solutions, on its strategic growth investment from GI Partners and TA Associates.

Cooley advised Lovable Labs, a Sweden-based artificial intelligence startup, on its $15 million pre-Series A financing round. The round was led by Creandum, with participation from Visionaries Club and angel investors, including Charlie Songhurst (Meta Platforms board), Adam D’Angelo and Thomas Wolf (Hugging Face), and Erik Bernhardsson (Modal Labs).

Lawyers Kevin Rooney, Karem Jarada, Carl Min, Shelby Saunders, Rebecca Ross, Christopher Kimball and Karen Tsai led the Cooley team advising Lovable, with support from paralegal Chu Lee and transactional quantitative analyst Jake Ironfield.

Cooley advised Baseten, the top inference platform for artificial intelligence (AI)-native products, on its $75 million Series C financing, bringing its total funding to $135 million.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.